![Rajesh Mannalal Agrawal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rajesh Mannalal Agrawal
Directeur Général chez
AJANTA PHARMA LIMITED
Fortune : 657 M $ au 31/07/2026
Profil
Rajesh Mannalal Agrawal is Joint Managing Director & Executive Director at Ajanta Pharma Ltd. since 1999.
Mr. Agrawal is Director at Gabs Investments Pvt Ltd. Mr. Agrawal is Director at Ajanta Pharma Philippines, Inc. Mr. Agrawal was Independent Non-Executive Director at SBFC Finance Ltd. from 2020 to 2025.
Mr. Agrawal earned an MBA from Bentley University in 1999.
Mr. Agrawal completed undergraduate studies at the University of Buckingham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AJANTA PHARMA LIMITED 14,47% | 19/08/2026 | 18 078 148 ( 14,47% ) | 657 M $ | 31/07/2026 |
Postes actifs de Rajesh Mannalal Agrawal
| Sociétés | Poste | Début |
|---|---|---|
| AJANTA PHARMA LIMITED | Directeur Général | - |
Ajanta Pharma Philippines, Inc.
 Ajanta Pharma Philippines, Inc. Part of Ajanta Pharma Ltd., Ajanta Pharma Philippines, Inc. is a wholly owned subsidiary of a pharmaceutical supplier specializing in first-to-market pharmaceutical compounds, unique therapeutically optimized combinations, and value-branded equivalents. The company is located in the Philippines. The Filipino company offers a diverse portfolio targeting various conditions including type 2 diabetes, hypertension, allergic rhinitis, COPD, benign prostatic hyperplasia, vertigo, and hyperuricemia in chronic kidney disease. Key products include Asenza Plus (a combination of pioglitazone hydrochloride and glimepiride for improved glycemic control in type 2 diabetes), Maxivent (doxofylline for bronchial asthma and COPD), Nebiloc CCB (nebivolol hydrochloride and amlodipine besilate for essential hypertension and chronic stable angina), and Co-Altria (montelukast sodium and levocetirizine dihydrochloride for allergic rhinitis). Additional products include fixed dose combinations for diabetes and cholesterol management, as well as treatments for benign prostatic hyperplasia and other conditions. Ajanta Pharma Philippines also provides patient education resources, career opportunities, and publishes articles on pharmaceutical developments and treatments. The company's products are prescription-based and come with detailed prescribing information. | Directeur/Membre du Conseil | - |
Gabs Investments Pvt Ltd.
 Gabs Investments Pvt Ltd. Financial ConglomeratesFinance Provides investment services | Directeur/Membre du Conseil | - |
Anciens postes connus de Rajesh Mannalal Agrawal
| Sociétés | Poste | Fin |
|---|---|---|
| SBFC FINANCE LIMITED | Directeur/Membre du Conseil | 12/11/2025 |
Formation de Rajesh Mannalal Agrawal
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
43
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Ajanta Pharma Ltd.
 Ajanta Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Bentley University
 Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Buckingham
 University of Buckingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gabs Investments Pvt Ltd.
Gabs Investments Pvt Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
Ajanta Pharma Philippines, Inc.
Ajanta Pharma Philippines, Inc. Part of Ajanta Pharma Ltd., Ajanta Pharma Philippines, Inc. is a wholly owned subsidiary of a pharmaceutical supplier specializing in first-to-market pharmaceutical compounds, unique therapeutically optimized combinations, and value-branded equivalents. The company is located in the Philippines. The Filipino company offers a diverse portfolio targeting various conditions including type 2 diabetes, hypertension, allergic rhinitis, COPD, benign prostatic hyperplasia, vertigo, and hyperuricemia in chronic kidney disease. Key products include Asenza Plus (a combination of pioglitazone hydrochloride and glimepiride for improved glycemic control in type 2 diabetes), Maxivent (doxofylline for bronchial asthma and COPD), Nebiloc CCB (nebivolol hydrochloride and amlodipine besilate for essential hypertension and chronic stable angina), and Co-Altria (montelukast sodium and levocetirizine dihydrochloride for allergic rhinitis). Additional products include fixed dose combinations for diabetes and cholesterol management, as well as treatments for benign prostatic hyperplasia and other conditions. Ajanta Pharma Philippines also provides patient education resources, career opportunities, and publishes articles on pharmaceutical developments and treatments. The company's products are prescription-based and come with detailed prescribing information. | |
SBFC Finance Ltd.
 SBFC Finance Ltd. Finance/Rental/LeasingFinance Provides financing solutions | Finance |
